This bill establishes a new Office of Novel Therapeutics within the Veterans Health Administration to prepare for and implement emerging mental health treatments, particularly psychedelic-assisted therapies currently under FDA evaluation. The Office will develop national policies, clinical standards, training programs, and implementation plans for these novel treatments while coordinating with the FDA and other federal agencies. The VA will designate centers of excellence at medical facilities across the country to lead research and training, establish a veteran advisory committee to provide patient input, and conduct a clinical implementation program to test these therapies' effectiveness and feasibility in real-world VA settings. The bill requires the VA to submit a national preparedness strategy within 180 days and provide annual reports to Congress on research activities, patient outcomes, safety events, and workforce needs. This legislation primarily affects veterans seeking mental health treatment for conditions like PTSD, depression, and substance use disorders, as well as VA healthcare providers and clinical staff.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.